Castleark Management’s BridgeBio Pharma BBIO Stock Holding History

Castleark Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.85M	Sell	78,497 -3,240	-4%	-$227K	0.16%	147
2026 Q1	$6.07M	Sell	81,737 -32,280	-28%	-$2.34M	0.2%	127
2025 Q4	$8.72M	Sell	114,017 -9,690	-8%	-$636K	0.26%	82
2025 Q3	$6.43M	Buy	123,707 +45,867	+59%	+$2.24M	0.18%	127
2025 Q2	$3.36M	Sell	77,840 -29,140	-27%	-$1.06M	0.1%	151
2025 Q1	$3.7M	Buy	+106,980	New	+$3.61M	0.13%	149
2022 Q4	–	Sell	-90,470	Closed	-$899K	–	287
2022 Q3	$899K	Buy	+90,470	New	+$940K	0.05%	195
2021 Q3	–	Sell	-46,457	Closed	-$2.83M	–	334
2021 Q2	$2.83M	Sell	46,457 -60,053	-56%	-$3.43M	0.1%	174
2021 Q1	$6.56M	Buy	+106,510	New	+$6.97M	0.24%	119

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Castleark Management's BBIO Position: Q2 2026 in Review

Castleark Management reduced its BridgeBio Pharma (BBIO) stake by 4% in Q2 2026, selling an estimated $227K and leaving 78,497 shares worth $5.85M. The position accounts for 0.16% of the portfolio, ranked #147.

Castleark Management first reported a position in BBIO in Q1 2021 and has held it in 9 quarters since. The position peaked at $8.72M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Castleark Management held 78,497 shares of BridgeBio Pharma worth $5.85M as of Q2 2026.
Castleark Management sold 3,240 BridgeBio Pharma shares in Q2 2026, an estimated $227K.
BridgeBio Pharma made up 0.16% of Castleark Management's portfolio in Q2 2026, its #147 holding.
Castleark Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 9 quarters since.
Castleark Management's BridgeBio Pharma position peaked at $8.72M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.